CMS Weighs Merits Of New Pass-Through Payments For Aquabeam System, Eluvia Stents In OPPS Proposal

 
• By Sue Darcey

The US Medicare agency has been scrutinizing two new devices that have generated some buzz within the industry for pass-through payment status under its proposed 2020 Outpatient Prospective Payment System (OPPS) rules. The devices are Procept BioRobotic’s AquaBeam System for removal of prostate tissue in men with urinary tract symptoms, and Boston Scientific’s Eluvia drug-eluting stent for treatment of peripheral artery disease.

Vintage Water bokeh background
The Medicare agency has been scrutinizing the evidence to support a pass-through payment for the AquaBeam System under its proposed 2020 OPPS rule

More from Policy & Regulation

More from Medtech Insight